Compare ATHA & ALUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ATHA | ALUR |
|---|---|---|
| Founded | 2011 | 2009 |
| Country | United States | United States |
| Employees | 26 | N/A |
| Industry | Medicinal Chemicals and Botanical Products | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.0M | 18.9M |
| IPO Year | 2020 | N/A |
| Metric | ATHA | ALUR |
|---|---|---|
| Price | $6.91 | $1.88 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $9.25 |
| AVG Volume (30 Days) | ★ 3.2M | 60.3K |
| Earning Date | 02-26-2026 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $17,208,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $15.47 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.20 | $1.02 |
| 52 Week High | $8.36 | $16.81 |
| Indicator | ATHA | ALUR |
|---|---|---|
| Relative Strength Index (RSI) | 62.50 | 66.17 |
| Support Level | $6.41 | $1.18 |
| Resistance Level | $7.64 | $1.48 |
| Average True Range (ATR) | 0.69 | 0.13 |
| MACD | 0.03 | 0.04 |
| Stochastic Oscillator | 68.86 | 95.24 |
Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) is a small molecule drug candidate designed to enhance the activity of the neurotrophic hepatocyte growth factor (HGF) system; ATH-1020 a novel, orally available, next-generation small molecule drug candidate designed to positively modulate the neurotrophic HGF system; ATH-1105 is a novel, orally available, next-generation, small molecule drug candidate designed to positively modulate the neurotrophic HGF system.
Allurion Technologies Inc is a medical device company that focuses on creating a weight loss platform to treat overweight patients. Its platform, the Allurion Program, features the world's first and only swallowable, procedure-less intragastric balloon for weight loss and offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion VCS. Its proprietary intragastric balloon, the Allurion Balloon, is in the form of a swallowed capsule that is administered to patients under the guidance of a healthcare provider without surgery, endoscopy, or anesthesia.